- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01901991
Localization of Nonpalpable Breast Lesions
A Randomized Study of Localization of Nonpalpable Breast Lesions - RSL vs WGL
Each year the Danish mammography-screening programme identifies a large number of patients with small non-palpable breast cancers or precancerous lesions. The majority of these patients are suitable for breast conserving surgery (BCS). The object of BCS is to remove the suspicious lesion completely without removing excess healthy breast tissue. To obtain this accurate lesion localization is essential.
Until today the standard procedure in Denmark has been wire guided localization (WGL). Although the method has been utilized for a number of years it has several disadvantages. Often inaccurate lesion localization leads to incomplete lesion removal (positive margin) and subsequently reoperation. It can postpone the additional systemic treatment, offered after the operation. Other disadvantages are poor cosmetic outcome and inconvenient planning for the patient and the departments involved. The wire needs to be placed on the day of the operation, which decreases the flexibility of the procedure.
The purpose of this study is to test a new method named radioactive seed localization (RSL). The method uses a small titanium seed containing radioactive iodine. It will be placed in the centre of the lesion, and during the operation, the surgeon can locate it with a handheld gamma probe. The seed can be placed a few days in advance, which means a more flexible course of treatment. The method seems promising with regards to reoperation rates, but it needs further testing.
Hypothesis:
RSL is a more accurate method, for localization of nonpalpable breast lesions, than WGL. Using RSL obtains, to a great extent, adequate negative margins, resulting in a reduced number of re-operations.
The study will be performed as a randomised clinical trial, where the two methods will be compared to each other. The trial will be performed at the department of breast surgery at Rigshospitalet and include patients with nonpalpable breast lesions. Besides reoperation rates, duration of the surgical procedure and the amount of removed breast tissue will be compared.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Østerbro
-
Copenhagen, Østerbro, Denmark, 2100
- Rigshospitalet (Copenhagen University Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with nonpalpable breast lesions, carcinoma in situ or invasive carcinoma, where preoperative lesion localization is necessary.
- All age groups, minimum 18 years
Exclusion criteria:
- Patients with benign nonpalpable breast lesions.
- Patients who are unable to comprehend the information.
- Patients who are pregnant, breastfeeding or have children < 3 years.
- Patients who have lesions, which requires more than two wires or seeds for localization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radioactive seed localization (RSL)
Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL). In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL. |
Localization of nonpalpable breast lesions with Radioactive seed localization
|
Active Comparator: Wire-guided localization (WGL)
Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL). In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL. |
Localization of nonpalpable breast lesions with Wire-guided localization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Re-operation rate due to positive microscopic margins detected at the final pathological evaluation.
Time Frame: Re-operation within 3 months after the initial breast conserving surgery.
|
Re-operation within 3 months after the initial breast conserving surgery.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Amount of excised breast tissue in relation to tumour size.
Time Frame: 3 months.
|
3 months.
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of the surgical procedure.
Time Frame: 3 months.
|
3 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Niels Kroman, Professor, Rigshospitalet (Copenhagen University Hospital), Department of Breast Surgery
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R72-A4701-13-S9
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma in Situ
-
Yale UniversityPatient-Centered Outcomes Research InstituteCompletedDuctal Carcinoma In SituUnited States
-
Sunnybrook Health Sciences CentreTerminated
-
Windy Hill Medical, Inc.UnknownDuctal Carcinoma In SituUnited States
-
Duke UniversityWithdrawnBreast Reconstruction | Ductal Carcinoma In-situUnited States
-
M.D. Anderson Cancer CenterCompletedDuctal Carcinoma In SituUnited States
-
Xoft, Inc.Icad, Inc.WithdrawnDuctal Carcinoma In Situ | Invasive Ductal Carcinoma
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...Active, not recruitingDuctal Carcinoma in Situ of the BreastUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingCancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Stanford UniversityRecruitingSurgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)Ductal Breast Carcinoma in SituUnited States
Clinical Trials on Radioactive seed localization (RSL)
-
Wake Forest University Health SciencesCompleted
-
Hospital Clinic of BarcelonaRecruiting
-
Centre Antoine LacassagneCompleted
-
The University of Hong KongEndomagnetics Ltd.RecruitingBreast Neoplasm | Chemotherapy EffectHong Kong
-
VA Puget Sound Health Care SystemSchiffler Cancer CenterUnknown
-
McMaster UniversityCanadian Breast Cancer FoundationCompletedBreast Cancer Invasive Nos | Stage 0 Breast CarcinomaCanada
-
Clarunis - Universitäres Bauchzentrum BaselCompletedLiver Cirrhosis | Liver CancerSwitzerland
-
VA Puget Sound Health Care SystemDr. Gregory Merrick; Theragenics CorporationUnknown
-
Peking University Third HospitalRecruitingThoracic Cancer | Radioactive Iodine-125 Brachytherapy | 3D Printing Coplanar Template | Nuclear Radiation EffectsChina
-
Peking University Third HospitalShengli Oilfield Central Hospital; First Affiliated Hospital of the Army Medical...CompletedDesmoid Tumor | Brachytherapy | Radioactive Iodine-125 Seed ImplantationChina